Aim­ing to up­root the mar­ket for asth­ma at­tacks, As­traZeneca and Avil­lion tout two PhI­II wins for in­haled com­bo drug

A col­lab­o­ra­tion launched in 2018 be­tween As­traZeneca and British com­pa­ny Avil­lion is bear­ing new fruit Thurs­day for a se­vere asth­ma pro­gram.

The As­traZeneca and Avil­lion can­di­date, dubbed PT027, met all pri­ma­ry end­points in two Phase III stud­ies, the com­pa­nies an­nounced Thurs­day. A com­bi­na­tion of the short-act­ing be­ta2-ag­o­nist (SA­BA) al­buterol — a com­mon asth­ma med­ica­tion — and the in­haled cor­ti­cos­teroid budes­onide, PT027 is po­si­tioned to be­come the new stan­dard of care for asth­ma res­cue ther­a­py, As­traZeneca se­nior VP for res­pi­ra­to­ry and im­munol­o­gy Mi­na Makar told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER